CONCLUSIONS & FUTURE SCOPE:
In conclusion, our study identifies that HCT is the largest contributor
to healthcare utilization in WAS patients. It also identifies the
healthcare disparities based on race and socioeconomic status. There is
a disparity in use of splenectomy in our database compared to other
studies which suggest a change in practice in this immunodeficient
population. We also found that only a few centers across the nation
contribute to maximum inpatient admissions for WAS, suggesting need for
wider resources for this very rare disease. There is a need for a bigger
national database and longitudinal studies to follow these patients and
assess for long term complications.
Ethics approval : Not applicable
Consent for publication : Not applicable
Availability of data and material : The data that support the
findings of this study are available from KIDS database at
www.hcup-us.ahrq.gov/kidoverview.jsp.
Restrictions apply to the availability of these data, which were used
under license for this study. Data are available
available on request and with permission from HCUP.
Competing interests : None of the authors have any financial or
non-financial competing interests to declare.
Funding : The authors have no funding to declare.
Authors’ contributions : JD and SA were responsible for
conceptualizing the project with NA and DS. SM and NP were involved in
statistical analysis of the dataset. DS and NA were responsible for
drafting the manuscript and review of literature. All authors read and
approved the final manuscript.
Acknowledgements : To Anjali Shekar, MD for providing consent
and access to the KIDS dataset.
REFERENCES :
- Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott Aldrich
syndrome: diagnosis, clinical and laboratory manifestations, and
treatment. Biol Blood Marrow Transplant 2009;15 Suppl 1:84–90.
- Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a
comprehensive review. Ann N Y Acad Sci 2013;1285:26–43.
- Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome:
Diagnosis, current management, and emerging treatments. Appl Clin
Genet 2014;7:55-66.
- Parkman R et al. Complete correction of the Wiskott-Aldrich Syndrome
by allogeneic bone-marrow transplantation. N Engl J Med
1978;298:921-927.
- Filipovich AH et al. Impact of donor type on outcome of bone marrow
transplantation for Wiskott-Aldrich syndrome: collaborative study of
the International Bone Marrow Transplant Registry and the National
Marrow Donor Program. Blood 2001;97:1598-1603.
- Shin CR et al. Outcomes following hematopoietic cell transplantation
for Wiskott–Aldrich syndrome. Bone Marrow Transplantation
2012;47:1428-1435.
- HCUP Kids’ Inpatient Database (KID). Healthcare Cost and Utilization
Project (HCUP). 2006 and 2009. Agency for Healthcare Research and
Quality, Rockville,
MD. www.hcup-us.ahrq.gov/kidoverview.jsp.
- Houchens R. Inferences with HCUP State Databases Final Report. HCUP
Methods Series Report. U.S. Agency for Healthcare Research and
Quality, 2010.
https://www.hcup-us.ahrq.gov/reports/methods/2010_05.pdf
- HCUP Quality Control Procedures. Rockville, MD: Agency for Healthcare
Research and Quality.
https://www.hcup-us.ahrq.gov/db/quality.jsp
- Steiner C, Elixhauser A, Schnaier J. The healthcare cost and
utilization project: an overview. Eff Clin Pract
2002;5:143-151.
- Heckbert SR et al. Comparison of self-report, hospital discharge
codes, and adjudication of cardiovascular events in the Women’s Health
Initiative. Am J Epidemiol 2004;160:1152-1158.
- Prchal JT et al. Wiskott-Aldrich syndrome : cellular impairments and
their implication for cellular detection. Blood 1980;56:1048-1054.
- Fearson ER, Kohn DB, Winkelstein JA, Vogelstein B, Blaese RM. Carrier
detection in the Wiskott Aldrich syndrome. Blood 1988;72:1735-1739.
- Greer WL, Kwong PC, Peacocke M, Ip R, Rubin LA, Siminovitch KA.
X-chromosome inactivation in Wiskott-Aldrich syndrome: a marker for
detection of the carrier state and identification of cell lineages
expressing gene defect. Genomics 1989;4:60-67.
- Mantuano E et al. Analysis of X-chromosome inactivation in bone marrow
precursors from carriers of Wiskott-Aldrich syndrome and X-linked
severe combined immunodeficiency : evidence the Wiskott-Aldrich gene
is expressed prior to granulocyte-macrophage colony-forming unit.
Immunodeficiency 1993;4:271-276.
- Wengler G, Gorlin JB, Williamson JM, Rosen FS, Bing DH. Nonrandom
inactivation of the X chromosome in early lineage hematopoietic cells
in carriers of Wiskott Aldrich syndrome. Blood 1995;85:2471-2477.
- Lutskiy MI, Sasahara Y, Kenney DM, Rosen FS, Remold-O’Donnell E.
Wiskott-Aldrich syndrome in a female. Blood 2002;100(8):2763-2768.
- Tornai I, Kiss A, Laczko J. Wiskott-Aldrich syndrome in a heterozygous
carrier woman. Eur J Haematol 1989;42:501-502.
- Lin CY, Hsu HC. Acute immune complex mediated glomerulonephritis in a
Chinese girl with Wiskott Aldrich syndrome variant. Ann Allergy
1984;53:74-78.
- Russell SJ, Nisen PD. Random X chromosome inactivation in a female
with a variant of Wiskott Aldrich syndrome. Br J Haematol
1995;90:210-212.
- Conley ME, Wang WC, Parolini O, Shapiro DN, Campana D, Siminovitch KA.
Atypical Wiskott-Aldrich syndome in a girl. Blood 1992;80:1264-1269.
- Parolini O et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl
J Med 1998;338:291-295.
- Puck JM, Willard HF. X inactivation in females with X linked disease.
N Engl J Med. 1998;338:325-328.
- Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and
allogeneic hematopoietic cell transplantation in the United States: a
study using a large national private claims database. Bone Marrow
Transplant 2013;48(2):294-300.
- Ballen KK et al. Hospital length of stay in the first 100 days after
allogeneic hematopoietic cell transplantation for acute leukemia in
remission: comparison among alternative graft sources. Biol Blood
Marrow Transplant 2014;20(11):1819-1827.
- Cancer Facts & Figures 2019. Atlanta, American Cancer Society (2019).
https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html
- National Marrow Donor Program Registry Be A Match Statistics (2016).
https://bethematch.org/about-us/financial-information/annual-report/
- Barker JN et al. Racial disparities in access to HLA-matched unrelated
donor transplants: a prospective 1312-patient analysis. Blood Adv
2019;3(7):939-944.
- Sullivan KE, Mullen CA, Blease RM, Winkelstein JA. A multinational
survey of the Wiskott-Aldrich syndrome. J Pediatrics
1994;125(6):876-885.
- Imai K. et al. Clinical course of patients with WASP gene
mutations. Blood 2004;103(2):456-464.
- Dupuis-Girod S et al. Autoimmunity in Wiskott-Aldrich Syndrome: Risk
factors, Clinical features and outcome in a single center cohort of 55
patients. Pediatrics 2003;111(5):e622-e627.
- Schurman S, Candotti F. Autoimmunity in Wiskott-Aldrich syndrome.
Current Opinion in Rheumatology 2003;15(4):446-453.
- Mullen CA, Anderson KD, Blease RM. Splenectomy and/or bone marrow
transplantation in management of the Wiskott-Aldrich syndrome: long
term follow-up of 62 cases. Blood 1993;82(10):2961-2966.
- Ozsahin H. et al. Long-term outcome following hematopoietic stem-cell
transplantation in Wiskott-Aldrich syndrome: collaborative study of
the European Society for Immunodeficiencies and European Group for
Blood and Marrow Transplantation. Blood 2008;111(1):439-445.
- Moratto D et al. Long-term outcome and lineage-specific chimerism in
194 patients with Wiskott-Aldrich syndrome treated by hematopoietic
cell transplantation in the period 1980-2009: an international
collaborative study. Blood 2011;118(6):1675-168